I am expecting to see some complete or partial responses with the 4th and 5th cohorts. I am surprised at their slow enrollment of patients in this phase 1 study but hope the trial speeds up from here
Hey Plag, hope life has been good to you.
Absolutely they have the goods. As far as the SP I still say it sees the all time low again...sorry if that bugs anyone but there's no catalyst in the short term....that is how I see it. Of course there's always the chance some great news hits out of nowhere. I'm thinking when the results are released from the next trial whether that's phase II or III the run to....whatever...$20...$40...$100 begins.. Several years away more than likely.
Either way I am holding some....so...good luck to all.
I agree. Errors in measuring the tumors and possibly an anomaly are the major sources contributing to the ending of the 145 trial. I think it has, like you said, taught the company a lot. (not to mention what they say to the press; they are much more quiet these days) I like how they modified 1456 and so far are getting more and a bigger bang out of it. If this guy, who was with Merck, can come in and help them through rough patch then even better.
Nice seeing your post.......Shorty....do we have the goods? so far I;m holding on.......I saw your post that suggested a big pull back before the climb up......any thoughts?
Just an educated guess you'll think twice before buying a bio that's up 700% off it's all time low. That's right....from 3ish just to the secondary offering at $21. Course my opinion is biased considering I was in big back between $3.50 ish and $5...then selling just about everything from $12 ish to $33.
Matter a fact...a measly 4 million shares at $21 was truly a thing of genius. That's what I love about this management....I have yet to see them play the wall street game like most bios are forced to do. I suspect that's the real reason why the stock's been punished. That's ok....they have the goods so they don't have to play. That's how you know a real bio vs all the sham bios....roughly 95 % are a sham and will never produce jack shieeeiat. Just a few days back I was listening to one of the financial channels and they were talking about "just start a bio and instant millionaire" and it's true...turning into a huge sham.
It's probably not going to end well.
Institutions and shareholders before they use any more. Unethical to be working at Endocyte using money raised with false facts. You should be ashamed of yourself if your going home with a Endocyte paycheck! That money is not yours. Lawsuits should end soon
Sorry I forgot to reply to your comments last week. Of course this is all speculation. A halted trial is a halted trial. With drug testing it doesn't matter why the data is what it is, all that matters is what the data says when reviewed per the trial guidelines. That said; in my opinion one of two things occurred in the PROCEED trial; 1) There was less resistance to single agent doxil (control arm) in a particular geographical area. Recall the arm testing 145 combined with doxil performed equally well as in prior successful trials thus it WAS NOT a ECYT drug issue. 2) There may have been human errors in measuring tumor growths or variations in techniques could have yielded more accurate answers which is what Dr. Mozley has focused on for part of his career. Do I personally believe EC145 was a failure? No, because it would have required significant data changes in the arm testing 145, but again it performed as well as historical successful trials. Something unusual (which is how it was quoted in their poster presentation) happened in the control given the medial PFS was more than double the preceding PRECEDENT trial. But there are not exceptions in trial guidelines. Today, I don't care much that PROCEED was halted because now we know 145 was not going to be the long term success of this company. I doubt they would have spent as much time pushing 145 today knowing 1456 is only 9 months behind. I still say that looking back, all of the "setbacks" in 2014 set the company up for the best long term plays in both allowing the company to advance the pipeline on its own and creating the most value for the long shareholders.
Sentiment: Strong Buy
I am sure he saw something good with ECYT when he was at Merck yes. I have expressed my view that while it was Mercks decision to end the partnership with 145 due to its successor (1456) being less than a year behind and to avoid milestone payments on the $850M remaining in the deal; ECYT has stated multiple times that they have chosen not to partner for EC1456 or EC1169 at this time. They also stated that any future agreement would include a 145/1456 bundle. Merck got their deal for 145 too early in my opinion. It doesn't mean Merck didn't want an agreement for 1456, but rather ECYT executives are confident enough to try and take 1456 to market alone and maximize shareholder value by not initially planning to split future revenues with a partner. Maybe their plan is to maximize company value and then sell the company? A partnership now would only benefit shareholders looking to create a spike immediately so that they can either try to make gains for losses suffered last year or turn a short term profit on shares purchased since last May. Taking EC1456 and EC1169 to market alone will benefit long shareholders in the end upon drugs success.
Sentiment: Strong Buy
The CT Order that was filed with the SEC on 4/14/15 pertains to exhibit 10.14 from form 10-K filed on March 13th, 2015. If you pull up the 10-k from 3/13/15 and scroll down to exhibit 10.14 you will see that it pertains to "Master License Agreement effective July 1, 2013 between Endocyte, Inc. and Purdue Research Foundation". This CT order protects the details of their license agreement.
Sentiment: Strong Buy
After taking more time to read all of the post descriptions and then re read your comment; we were both correct. I now see the comment you quoted. You took their usage of "folic acid-tubulysin conjugate" and replaced with EC1456 in your summary. I do not know if those two are exclusively interchangeable? Aside from that; I found the summary of all four posters very interesting and look forward to reading much more. It seems that even before 1456 is fully developed they are already looking to improve the next generation of SMDC's. With continual advancements, such as we are seeing, this company will no doubt achieve success. PROCEED being halted due to an unusually high median PFS in the control group, by more than double historical results, further supports the notion that trials with 1456 will achieve success. Time is all that is needed with ECYT. They will also achieve this success much faster than seen with 145. By testing four indications in the Phase I Part B and skipping Phase II; they can advance all indications simultaneously in Phase III and not one at a time as seen with 145. With success, it will skyrocket quickly. Sorry for my earlier correction. It was before I had enough time to fully read everything more closely.
Sentiment: Strong Buy
I look forward to reading all posters as well. One small but important correction to your statement; your quote states models resistant to 1456; From what I have read it addresses models resistant to 145. Maybe I missed something but that small change would have significantly different impacts.
... and today what words of wisdom do you wish to share after three strong days in the green. It broke the downward trend leading back to 5 dollars and if this is noise, then it is unusual. I see a train a coming
I'm really surprised no one has commented on this. The first two abstracts in the press release are about new conjugates that replace the folate with an anti-folate, producing a dual-drug that overcomes some of the models resistant to EC1456. " Similarly, tubulysin SMDCs constructed with AG94 and AG147 were found to produce curative activity using a dosing regimen where a folic acid-tubulysin conjugate did not." They're also targeting FR negative tumors by targeting the FR positive macrophages that help the tumors survive. I'm really looking forward to the last poster.
WEST LAFAYETTE, Ind., April 10, 2015 (GLOBE NEWSWIRE) -- Endocyte, Inc. (ECYT), a biopharmaceutical company and leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy in cancer and other serious diseases, today announced that four posters will be presented by Endocyte scientists at the 2015 Annual Meeting of the American Association for Cancer Research (AACR) to be held in Philadelphia, April 18-22, 2015.